Tang Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Tang Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-118,857	Closed	-$443K	–	194
2024 Q3	$443K	Hold	118,857	–	–	0.03%	136
2024 Q2	$666K	Hold	118,857	–	–	0.07%	101
2024 Q1	$623K	Hold	118,857	–	–	0.06%	92
2023 Q4	$622K	Hold	118,857	–	–	0.06%	111
2023 Q3	$1.87M	Hold	118,857	–	–	0.26%	73
2023 Q2	$2.31M	Buy	118,857 +38,857	+49%	+$922K	0.34%	67
2023 Q1	$2.27M	Sell	80,000 -38,857	-33%	-$1.15M	0.34%	63
2022 Q4	$3.47M	Hold	118,857	–	–	0.5%	48
2022 Q3	$3.14M	Buy	+118,857	New	+$4.36M	0.39%	59
2020 Q4	–	Sell	-62,262	Closed	-$2.65M	–	22
2020 Q3	$2.65M	Sell	62,262 -193,354	-76%	-$8.46M	0.48%	16
2020 Q2	$12.3M	Hold	255,616	–	–	1.19%	13
2020 Q1	$11.8M	Buy	+255,616	New	+$12.8M	1.65%	12

Other funds holding EGRX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SLG

Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Tang Capital Management's EGRX Position: Q4 2024 in Review

Tang Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 118,857 shares — an estimated $443K sold.

Tang Capital Management first reported a position in EGRX in Q1 2020 and held it in 12 quarters. The position peaked at $12.3M in Q2 2020. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

Tang Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
Tang Capital Management sold 118,857 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $443K.
Tang Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and held it in 12 quarters.
Tang Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $12.3M in Q2 2020.
9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Tang Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.